HCC I/II approval to extend
Immunicum AB (publ) announced today that the Swedish Medical Products Agency and the Ethics Committee has approved that the phase I/II-study in liver cancer may be extended by up to six patients who will receive INTUVAX in combination with first-line treatments.
Read the press release here: Press release 151216 – HCC I-II approval for continuation
Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4913